会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明专利
    • BR9812727A
    • 2000-08-22
    • BR9812727
    • 1998-04-14
    • AMERICAN CYANAMID CO
    • LEVIN JEREMY IANZASK ARIEGU YANSONGALBRIGHT JAY DONALDDU XUEMEI
    • A61K31/437A61K31/4375A61K31/4427A61K31/444A61K31/47A61K31/4709A61K31/519A61K31/63A61K31/635A61K31/66A61P1/00A61P3/10A61P7/02A61P9/00A61P9/10A61P19/02A61P25/00A61P27/02A61P29/00A61P31/18A61P35/00A61P37/04A61P43/00C07D213/00C07D215/54C07D231/00C07D233/00C07D239/00C07D261/00C07D275/00C07D333/00C07D401/12C07D409/14C07D471/04C07D487/04C07D495/04C07D498/04C07D513/04C07F9/547A61K31/44
    • This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF- alpha converting enzyme (TACE, tumor necrosis factor- alpha converting enzyme) of formula (B) wherein (B) is (1), (2), or (3); P and Q are (4) or (5), provided that when P is (4), Q is (5), and vice versa; T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R ; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; (6) is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteroatoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri- substituted with R ; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri-substituted with R ; R is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, -(CH2)nZ, -OR , -CN, -COR , perfluoroalkyl of 1-4 carbon atoms, -CONR R , -S(O)xR -OPO(OR )OR , -PO(OR )R , -OC(O)NR R3, -COOR , -CONR R , -SO3H, -NR R , -NR COR , -NR COOR , -SO2NR R , -NR CONR R , -NR C(=NR )NR R , -SO2NHCOR , -CONHSO2R , -tetrazol-5-yl, -SO2NHCN, -SO2NHCONR R , or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R ; R and R are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n = 1-6; x = 0-2 or a pharmaceutically acceptable salt thereof.